Kathleen Hawker

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data
    Kathleen Hawker
    Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Neurol 21:S19-25. 2008
  2. ncbi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
  3. ncbi Progressive multiple sclerosis: characteristics and management
    Kathleen Hawker
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neurol Clin 29:423-34. 2011
  4. ncbi Multiple sclerosis
    Kathleen Hawker
    Multiple Sclerosis Program, Department of Neurology, University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Room J3.134, Dallas, TX 75390-9036, USA
    Prim Care 31:201-26. 2004
  5. ncbi Mycophenolate mofetil in multiple sclerosis
    Elliot M Frohman
    Department of Neurology, University of Texas, Southwestern Medical Center at Dallas, USA
    Clin Neuropharmacol 27:80-3. 2004
  6. ncbi A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)
    Gina M Remington
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Ther Adv Neurol Disord 3:3-13. 2010

Detail Information

Publications6

  1. ncbi B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data
    Kathleen Hawker
    Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Neurol 21:S19-25. 2008
    ..This article describes the mechanism of action behind B-cell-targeted depletion therapies in development and reviews available clinical data...
  2. ncbi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
  3. ncbi Progressive multiple sclerosis: characteristics and management
    Kathleen Hawker
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neurol Clin 29:423-34. 2011
    ..This article reviews magnetic resonance imaging and clinical data that show that progression may occur early in the course of MS and specific subsets of progressive patients may respond to disease modifying drugs...
  4. ncbi Multiple sclerosis
    Kathleen Hawker
    Multiple Sclerosis Program, Department of Neurology, University of Texas, Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Room J3.134, Dallas, TX 75390-9036, USA
    Prim Care 31:201-26. 2004
  5. ncbi Mycophenolate mofetil in multiple sclerosis
    Elliot M Frohman
    Department of Neurology, University of Texas, Southwestern Medical Center at Dallas, USA
    Clin Neuropharmacol 27:80-3. 2004
    ..To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS)...
  6. ncbi A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS)
    Gina M Remington
    Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Ther Adv Neurol Disord 3:3-13. 2010
    ..Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of MMF in MS appears warranted...